Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
BE
MCID: BRR014
MIFTS: 64

Barrett Esophagus (BE)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Barrett Esophagus

About this section

MalaCards integrated aliases for Barrett Esophagus:

Name: Barrett Esophagus 56 12 52 73 36 29 54 43 39 71
Barrett's Esophagus 12 52 15 17
Barrett Esophagus/esophageal Adenocarcinoma 56 13 6
Barrett's Ulcer of Esophagus 12 71
Esophageal Adenocarcinoma 58 17
Ulcerative Esophagitis 12 71
Barrett Metaplasia 56 73
Barrett Syndrome 74 52
Chronic Peptic Ulcer and Esophagitis Syndrome 52
Barrett's Esophagus with Esophagitis 12
Adenocarcinoma of the Esophagus 58
Adenocarcinoma of Esophagus 71
Peptic Ulcer of Esophagus 71
Esophagitis-Peptic Ulcer 52
Columnar-Like Esophagus 52
Barrett's Oesophagus 12
Barretts Syndrome 12
Barrett Ulcer 52
Be 73

Characteristics:

Orphanet epidemiological data:

58
adenocarcinoma of the esophagus
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Worldwide); Age of onset: Adult; Age of death: adult;

HPO:

31
barrett esophagus:
Inheritance somatic mutation


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Liver diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 12 DOID:9206
OMIM 56 614266
KEGG 36 H01901
ICD9CM 34 530.85
MeSH 43 D001471
NCIt 49 C2891
SNOMED-CT 67 76355008
ICD10 32 K22.7 K22.70
ICD10 via Orphanet 33 C15.2 C15.5
UMLS via Orphanet 72 C0279628
Orphanet 58 ORPHA99976
UMLS 71 C0004763 C0267075 C0279628 more
Sources

Summaries for Barrett Esophagus

About this section
KEGG : 36 Barrett esophagus (BE) is the premalignant lesion of esophageal adenocarcinoma (EAC) defined as specialized intestinal metaplasia (SIM) of the tubular esophagus. According to some studies, the incidence of the esophageal adenocarcinoma in patients with BE is of about 0.5% per year. The major pathogenetic factor in the development of BE is represented by the gastroesophageal reflux disease. BE is characterized by the replacement of the normal squamous epithelium with the columnar epithelium, when the healing of the lesion occurs. Because only a minority of patients (around 10-15%) with gastroesophageal reflux disease have BE, additional factors that play important roles in determining the development of BE must concur. Another frequent association with BE, is represented by nitrate, an increased age, Caucasian race, male sex and hiatal hernia. Recently, it has been reported that mutations in MSR1, ASCC1, and CTHRC1 are associated with this disease.

MalaCards based summary : Barrett Esophagus, also known as barrett's esophagus, is related to vaginal cancer and gastroesophageal reflux. An important gene associated with Barrett Esophagus is CTHRC1 (Collagen Triple Helix Repeat Containing 1), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Esomeprazole and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and brain, and related phenotypes are obesity and gastroesophageal reflux

NIH Rare Diseases : 52 Barrett esophagus is a condition in which the lining of the esophagus (the tube that carries food from the throat to the stomach) is replaced by tissue that is similar to the lining of the intestines. Although this change does not cause any specific signs or symptoms, it is typically diagnosed in people who have long-term gastroesophageal reflux disease (GERD) . The exact underlying cause of Barrett esophagus is not known; however, it generally occurs sporadically in people with no family history of the condition. Treatment varies by the severity of the condition and generally includes medications and life style modifications to ease the symptoms of GERD. Endoscopic or surgical treatments may be recommended in people with severe cases.

OMIM : 56 Barrett esophagus, or Barrett metaplasia, describes the phenotypic change of normal esophageal squamous epithelium to a columnar and intestinal-type epithelium. This metaplastic change is important because patients with Barrett esophagus have an increased risk of esophageal adenocarcinoma. The main cause of Barrett metaplasia is gastroesophageal reflux (GER; 109350). The retrograde movement of acid and bile salts from the stomach into the esophagus in this disease causes prolonged injury to the esophageal epithelium and induces chronic esophagitis, which in turn is believed to trigger the pathologic changes (summary by Wong et al., 2005). (614266)

UniProtKB/Swiss-Prot : 73 Barrett esophagus: A condition characterized by a metaplastic change in which normal esophageal squamous epithelium is replaced by a columnar and intestinal-type epithelium. Patients with Barrett esophagus have an increased risk of esophageal adenocarcinoma. The main cause of Barrett esophagus is gastroesophageal reflux. The retrograde movement of acid and bile salts from the stomach into the esophagus causes prolonged injury to the esophageal epithelium and induces chronic esophagitis, which in turn is believed to trigger the pathologic changes.

Wikipedia : 74 Barrett's esophagus is a condition in which there is an abnormal (metaplastic) change in the mucosal... more...

Sources

Related Diseases for Barrett Esophagus

About this section

Diseases related to Barrett Esophagus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 7068)
# Related Disease Score Top Affiliating Genes
1 vaginal cancer 32.2 TP53 KRT7 CDKN2A
2 gastroesophageal reflux 32.1 TP53 PTGS2 MSR1 GAST CTHRC1 CDX2
3 desmoid tumor 32.1 PTGS2 CDKN2A CCND1
4 esophagitis 32.1 TP53 PTGS2 GAST CTHRC1 CDKN2A ASCC1
5 peptic esophagitis 32.1 PTGS2 GAST CDX2
6 anus cancer 32.1 TP53 KRT7 CDKN2A
7 thymoma 32.0 TP53 KRT7 CDKN2A CCND1
8 merkel cell carcinoma 32.0 TP53 KRT7 KRT20 CDKN2A
9 spitz nevus 32.0 TP53 CDKN2A
10 nodular malignant melanoma 32.0 TP53 CDKN2A CCND1
11 ductal carcinoma in situ 31.9 TP53 PTGS2 CDKN2A CCND1
12 oral cancer 31.9 TP53 PTGS2 CDKN2A CCND1
13 malignant peripheral nerve sheath tumor 31.9 TP53 KRT7 CDKN2A CCND1
14 renal cell carcinoma, papillary, 1 31.9 TP53 KRT7 CDKN2A AMACR
15 adenocarcinoma 31.9 TP53 PTGS2 MSR1 KRT7 KRT20 CTHRC1
16 cystitis 31.9 TP53 PTGS2 KRT7 KRT20 CDX2
17 gallbladder cancer 31.8 TP53 PTGS2 KRT7 CDX2 CDKN2A CCND1
18 peptic ulcer disease 31.8 TP53 PTGS2 MUC5AC GAST
19 vulvar disease 31.7 TP53 KRT7 CDKN2A
20 cystitis cystica 31.7 KRT7 KRT20 CDX2
21 rhabdoid cancer 31.7 TP53 CDKN2A CCND1
22 linitis plastica 31.7 KRT7 KRT20 CDX2
23 squamous cell carcinoma 31.7 TP53 PTGS2 GSTP1 CDKN2A CCND1
24 larynx cancer 31.7 TP53 GSTP1 CDKN2A CCND1
25 penile cancer 31.7 TP53 CDKN2A CCND1
26 duodenum disease 31.7 TP53 MUC6 MUC5AC KRT7 GAST CDX2
27 leiomyosarcoma 31.7 TP53 CDKN2A CCND1
28 small cell carcinoma of the bladder 31.7 KRT7 KRT20
29 ovarian cancer 31.7 TP53 TFF1 PTGS2 MUC5AC KRT7 KRT20
30 bile duct cancer 31.6 TP53 MUC6 MUC5AC KRT7 KRT20 CDX2
31 pseudomyxoma peritonei 31.6 TP53 MUC6 MUC5AC KRT7 KRT20 CDX2
32 vulva cancer 31.6 TP53 KRT7 KRT20 CDKN2A CCND1
33 oncocytoma 31.6 KRT7 KRT20 AMACR
34 barrett's adenocarcinoma 31.5 TP53 PTGS2 GSTP1 CDKN2A
35 familial adenomatous polyposis 31.5 TP53 PTGS2 GSTP1 CCND1
36 adenocarcinoma in situ 31.5 KRT7 KRT20 CDX2 CDKN2A
37 adenoma 31.5 TP53 PTGS2 MUC6 MUC5AC KRT7 CDX2
38 colorectal adenoma 31.4 TP53 PTGS2 GSTP1 CDKN2A CCND1
39 squamous cell carcinoma, head and neck 31.3 TP53 PTGS2 GSTP1 CDKN2A CCND1
40 bile reflux 31.3 TFF1 PTGS2 MUC5AC GAST CDX2
41 esophagus adenocarcinoma 31.2 TP53 TFF3 PTGS2 CDX2 CDKN2A CCND1
42 small cell cancer of the lung 31.2 TP53 KRT7 KRT20 GAST
43 gastritis 31.1 TP53 TFF2 PTGS2 MUC6 GAST CDX2
44 papilloma 31.1 TP53 PTGS2 KRT7 KRT20 CDKN2A CCND1
45 tongue disease 31.1 TP53 CDKN2A CCND1
46 signet ring cell adenocarcinoma 31.1 TP53 MUC6 MUC5AC KRT7 KRT20 CDX2
47 cholecystitis 31.0 TP53 MUC6 MUC5AC CDKN2A
48 tubular adenocarcinoma 31.0 MUC5AC KRT7 KRT20 CDX2
49 colonic benign neoplasm 31.0 TP53 PTGS2 CDX2 CCND1
50 in situ carcinoma 31.0 TP53 CDKN2A CCND1

Graphical network of the top 20 diseases related to Barrett Esophagus:



Diseases related to Barrett Esophagus
Sources

Symptoms & Phenotypes for Barrett Esophagus

About this section

Human phenotypes related to Barrett Esophagus:

58 31 (show all 11)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 obesity 58 31 hallmark (90%) Very frequent (99-80%) HP:0001513
2 gastroesophageal reflux 58 31 hallmark (90%) Very frequent (99-80%) HP:0002020
3 feeding difficulties in infancy 58 31 hallmark (90%) Very frequent (99-80%) HP:0008872
4 barrett esophagus 58 31 hallmark (90%) Very frequent (99-80%) HP:0100580
5 esophageal carcinoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0011459
6 clinodactyly of the 5th toe 58 31 hallmark (90%) Very frequent (99-80%) HP:0001864
7 esophageal ulceration 31 hallmark (90%) HP:0004791
8 nausea and vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002017
9 cough 58 31 frequent (33%) Frequent (79-30%) HP:0012735
10 chest pain 58 31 frequent (33%) Frequent (79-30%) HP:0100749
11 lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002716

Clinical features from OMIM:

614266

MGI Mouse Phenotypes related to Barrett Esophagus:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10 CCND1 CDKN2A CDX2 GAST GPX2 MUC5AC
2 homeostasis/metabolism MP:0005376 9.83 AMACR CCND1 CDKN2A CDX2 CTHRC1 GAST
3 endocrine/exocrine gland MP:0005379 9.81 CCND1 CDKN2A CDX2 GAST GDF7 GPX2
4 neoplasm MP:0002006 9.17 CCND1 CDKN2A CDX2 GAST PTGS2 TFF1
Sources

Drugs & Therapeutics for Barrett Esophagus

About this section

Drugs for Barrett Esophagus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 267)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
2
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
3
Famotidine Approved Phase 4 76824-35-6 3325
4
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
5
Dinoprostone Approved Phase 4 363-24-6 5280360
6
Phenylephrine Approved Phase 4 59-42-7 6041
7
Zinc Approved, Investigational Phase 4 7440-66-6 32051
8
Irinotecan Approved, Investigational Phase 4 97682-44-5, 100286-90-6 60838
9
Levoleucovorin Approved, Investigational Phase 4 68538-85-2
10
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
11
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
12
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
13
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
14 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
15
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
16
Citalopram Approved Phase 4 59729-33-8 2771
17
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
18 Rebamipide Investigational Phase 4 90098-04-7
19
Polaprezinc Experimental Phase 4 107667-60-7
20
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
21 Gastrointestinal Agents Phase 4
22 Anti-Ulcer Agents Phase 4
23 Antacids Phase 4
24 Fibrinolytic Agents Phase 4
25 Platelet Aggregation Inhibitors Phase 4
26 Antipyretics Phase 4
27 Antioxidants Phase 4
28 Cyclooxygenase 2 Inhibitors Phase 4
29 Calcium, Dietary Phase 4
30 Topoisomerase Inhibitors Phase 4
31 topoisomerase I inhibitors Phase 4
32 Neuroprotective Agents Phase 4
33 Antiemetics Phase 4
34 Methylprednisolone Acetate Phase 4
35 Hormone Antagonists Phase 4
36 Antineoplastic Agents, Hormonal Phase 4
37 Hormones Phase 4
38 Anti-Inflammatory Agents Phase 4
39 Proton Pump Inhibitors Phase 4
40 glucocorticoids Phase 4
41 Autonomic Agents Phase 4
42 Neurotransmitter Agents Phase 4
43 Serotonin Uptake Inhibitors Phase 4
44 Psychotropic Drugs Phase 4
45 Antiparkinson Agents Phase 4
46 Muscarinic Antagonists Phase 4
47 Serotonin Agents Phase 4
48 Cholinergic Antagonists Phase 4
49 Cholinergic Agents Phase 4
50 Antidepressive Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 541)
# Name Status NCT ID Phase Drugs
1 Clinical and Medico-economic Evaluation of Radiofrequency Ablation Versus Oesophagectomy in the Treatment of High Grade Dysplasia in Barrett's Oesophagus Unknown status NCT02558504 Phase 4
2 Endoesophageal Cryotherapy: A New Technique For Ablating Barrett's Esophagus And Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
3 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
4 Esomeprazole or Famotidine in the Management of Aspirin Related Non-ulcer Dyspepsia - a Double Blind Randomized Control Study Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
5 Clinical Trial: Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and GERD-related Sleep Disturbances in Patients With Erosive GERD Unknown status NCT02277886 Phase 4 sodium alginate;esomeprazole
6 An Open-Label, 2-Way Crossover Study of Steady-State Intragastric pH Control Comparing 2 Dosage Regimens of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients Completed NCT00352261 Phase 4 Esomeprazole;Lansoprazole
7 A Multicenter, Double-blind, Three-way Crossover Intraesophageal and Intragastric pH Study of Three Esomeprazole Treatment Regimens in Documented Barrett's Esophagus Patients Completed NCT00637559 Phase 4 Esomeprazole Magnesium
8 A Multicenter, Open-label, Four-way Crossover Study of the Effects of Esomeprazole, Aspirin and Rofecoxib on Prostaglandin (PGE2) Production, Cyclooxygenase-2 Enzyme Activity and PCNA Expression in Patients With Barrett's Esophagus Completed NCT00637988 Phase 4 Esomeprazole;Aspirin;Rofecoxib
9 Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?: A Randomized Controlled Trial Completed NCT01093755 Phase 4 dexlansoprazole;Omeprazole
10 A STUDY OF CRYOSPRAY ABLATIONTM USING SURGICAL RESECTION SPECIMENS TO DETERMINE TREATMENT EFFECT, DEPTH OF INJURY, AND SIDE EFFECTS IN THE ESOPHAGUS (CSA Depth 3) Completed NCT00754468 Phase 4
11 Laparoscopic Nissen Fundoplication Combined With Posterior Gastropexy in Surgical Treatment of Gastroesophageal Reflux Disease Completed NCT00872755 Phase 4
12 A Pilot Study of Efficacy and Safety of Continuous Intravenous Infusion of Pantoprazole in the Treatment of Severe Erosive Esophagitis Completed NCT00133770 Phase 4 pantoprazole
13 Ablation of Gastric Dysplastic Mucosa by a Novel Endoscopic Radiofrequency Device. Completed NCT01523912 Phase 4
14 Efficacy of Zinc L-carnosine (Hepilor®) in Maintaining Remission of Gastroesophageal Reflux Disease: a Randomised, Double-blind, Placebo-controlled Study Recruiting NCT03467438 Phase 4 Zinc-l-carnosine
15 A Pilot Trial of Perioperative Genotype-Guided Irinotecan Dosing of mFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
16 Modulation of Esophageal Inflammation in Barrett&Apos;s Esophagus by Omega-3 Fatty Acids, a Double Blind Placebo Controlled Randomized Pilot Study Active, not recruiting NCT01733147 Phase 4 Omega-3 free fatty acids;Placebo
17 Reduction in Symptomatic Oesophageal Stricture Formation Post-two Stage Complete Barrett's Excision for High Grade Dysplasia or Early Adenocarcinoma With Short-term Steroid Therapy: A Randomized, Doubleblind, Placebo-controlled, Multicentre Trial. Not yet recruiting NCT02004782 Phase 4 Prednisolone;Placebo Oral Tablet
18 A Prospective Randomized Trial Comparing Yield of Confocal Endomicroscopy Guided Biopsies With Random Biopsies in the Detection of Specialized Columnar Epithelium in Barrett's Esophagus Terminated NCT01030263 Phase 4
19 A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia) Terminated NCT00526786 Phase 4
20 Reduction in Symptomatic Esophageal Stricture Formation Post-two Stage Complete Barrett's Excision for High Grade Dysplasia or Early Adenocarcinoma With Short-term Steroid Therapy: A Randomized, Double-blinded, Placebo-controlled, Multicenter Trial. Terminated NCT02039115 Phase 4 prednisone;placebo
21 Proton Pump Inhibitor (PPI's) and Selective Serotonin Reuptake Inhibitor Therapy (SSRI's) for the Management of Non Cardiac Chest Pain (NCCP) Terminated NCT02825342 Phase 4 Citalopram
22 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Unknown status NCT00357682 Phase 3 Esomeprazole;Esomeprazole;Aspirin
23 The Comparison of Value of Brachytherapy and Endoscopic Stenting With SEMS in Palliative Treatment of Dysphagia Resulting From Adenocarcinoma of the Esophago-Gastric Junction Unknown status NCT01786278 Phase 2, Phase 3
24 A Prospective Randomized Trial Comparing Endoscopic Radio Frequency Ablation (RFA) - STRETTA vs Sham Therapy for the Treatment of Refractory Gastroesophageal Reflux Disease Unknown status NCT02935881 Phase 3
25 A Prospective Randomized Trial Comparing Standard Chemotherapy Followed By Resection Versus Infusional Chemotherapy In Patients With Resectable Adenocarcinoma Of The Oesophagus Unknown status NCT00041262 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil
26 A Randomised Phase II/III Multi-Centre Clinical Trial of Definitive Chemotherapy, With or Without Cetuximab, in Carcinoma of the Oesophagus Unknown status NCT00509561 Phase 2, Phase 3 capecitabine;cisplatin
27 A PROSPECTIVE RANDOMISED NON SURGICAL TREATMENT OF OESOPHAGEAL CANCER WITH COMBINED CHEMOTHERAPY AND EXTERNAL BEAM IRRADIATION WITH VS WITHOUT HIGH-DOSE BRACHYTHERAPY Unknown status NCT00002884 Phase 3 chemotherapy;cisplatin;fluorouracil
28 A PROSPECTIVE RANDOMISED TRIAL OF INDUCTION CHEMOTHERAPY WITH 5-FU CONTINUOUS IV INFUSION AND CISPLATIN VERSUS SURGERY IN RESECTABLE ADENOCARCINOMA OF THE LOW THIRD OF THE ESOPHAGUS AND CARDIOESOPHAGEAL JUNCTION Unknown status NCT00002883 Phase 3 cisplatin;fluorouracil
29 Two-arm Phase III Trial Comparing Different Time of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Unknown status NCT02628665 Phase 3 photosensitizer(photofrin)
30 Prospective Randomized Phase III Study of Laparoscopic Repair of Giant Hiatal Hernias With Nitinol-framed Lightweight Polytetrafluoroethylene Mesh Unknown status NCT01780285 Phase 3
31 Confocal Laser Endomicroscopy for Improved Diagnosis of Barrett's Esophagus and Associated Neoplasia Completed NCT00487695 Phase 3
32 Biomarkers in Phototherapy of Barrett's Esophagus Completed NCT00587600 Phase 2, Phase 3
33 Melatonin Associated to Acid Inhibition for Chemoprevention in Barret Esophagus: a Pilot Study Completed NCT01566474 Phase 3 Omeprazole;Melatonin
34 An Open-label, Parallel-group, Multi-centre, Phase I/III Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Once-daily Oral Administration of D961H 10 mg and D961H 20 mg in Japanese Paediatric Patients 1 to 14 Years Old With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3 D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
35 Randomised Phase III Study of Docetaxel vs Active Symptom Control in Patients With Relapsed Oesophago-gastric Adenocarcinoma Completed NCT00978549 Phase 3 docetaxel;steroid therapy
36 The Evaluation of Effectiveness Between Empirical and Guided Therapy for Unexplained Non-Cardiac Chest Pain Completed NCT03319121 Phase 2, Phase 3 Empirical therapy group;Guided therapy group
37 A PHASE III INTERGROUP RANDOMIZED COMPARISON OF COMBINED MODALITY THERAPY FOR CARCINOMA OF THE ESOPHAGUS: HIGH-DOSE VS CONVENTIONAL-DOSE RADIATION THERAPY Completed NCT00002631 Phase 3 chemotherapy;cisplatin;fluorouracil
38 Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Gefitinib (Iressa®) Versus Placebo in Esophageal Cancer Progressing After Chemotherapy Completed NCT01243398 Phase 3
39 Randomized Study of Pre-Operative Radio-Chemotherapy Versus Surgery Alone in Thoracic Esophageal Cancer Deemed to be Resectable Completed NCT00047112 Phase 3 cisplatin;fluorouracil
40 A Prospective Randomized Phase III Trial Comparing Trimodality Therapy (Cisplatin, 5-FU, Radiotherapy, and Surgery) to Surgery Alone for Esophageal Cancer Completed NCT00003118 Phase 3 cisplatin;fluorouracil
41 A Multi-center, Double-blind, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Sodium Alginate Oral Suspension (50 mg/ml) in Comparison to Omeprazole (20 mg/Cap) to Treat Non-erosive Gastro-esophageal Reflux Disease (NERD) Completed NCT01338077 Phase 3 Sodium alginate;Omeprazole
42 Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma Completed NCT00052910 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil;leucovorin calcium
43 An Open Label, Sequential Multi-Center Multi Dose Study Of G17T Immunogen In Combination With Cisplatin (CDDP) And 5-Fluorouracil (5-FU) In Subjects With Metastatic Or Locally Recurrent Gastric Or Gastroesophageal Cancer Previously Untreated With Chemotherapy For Advanced Disease (Stage IV) Completed NCT00020787 Phase 3 cisplatin;fluorouracil
44 Phase II-III Study Comparing Radiochemotherapy With the FOLFOX Regimen Versus Radiochemotherapy With 5FU-cisplatin (Herskovic Regimen) in First Line Treatment of Patients With Inoperable Oesophageal Cancer. Completed NCT00861094 Phase 2, Phase 3 cisplatin;5-FU;oxaliplatin;Folinic Acid
45 Multimodal Therapy With and Without Cetuximab in Patients With Locally Advanced Esophageal Carcinoma - An Open-Label Phase III Trial Completed NCT01107639 Phase 3 cisplatin;docetaxel
46 Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus Recruiting NCT02509286 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
47 Efficacy and Safety Study of the Combined Modality Therapy in Patients With Potentially Resectable, Locally Advanced Adenocarcinoma of the Esophago-gastric Junction With Preoperative Chemo- and Chemoradiation Followed by Surgical Resection Recruiting NCT01523015 Phase 2, Phase 3
48 An Open Label, Parallel Group, Multi-centre, Phase III Study to Assess the Efficacy and Safety of D961H for the Maintenance Therapy Following Initial Treatment in Japanese Paediatric Patients With Reflux Esophagitis and for the Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer in Japanese Paediatric Patients Treated With Non-steroidal Anti-inflammatory Drugs or Low-dose Aspirin Recruiting NCT03553563 Phase 3 D961H capsule 10mg;D961H sachet 10mg
49 PreOperative Treatment With chEmotheRapy or chemoRAdiatioN in esophaGeal or gastroEsophageal adenocaRcinoma Recruiting NCT01404156 Phase 2, Phase 3 (Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel
50 Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer Recruiting NCT03801876 Phase 3 Carboplatin;Paclitaxel

Search NIH Clinical Center for Barrett Esophagus

Cochrane evidence based reviews: barrett esophagus

Sources

Genetic Tests for Barrett Esophagus

About this section

Genetic tests related to Barrett Esophagus:

# Genetic test Affiliating Genes
1 Barrett Esophagus 29 ASCC1 CTHRC1 MSR1
Sources

Anatomical Context for Barrett Esophagus

About this section

MalaCards organs/tissues related to Barrett Esophagus:

40
T Cells, Bone, Brain, Heart, Breast, Skin, Thyroid
Sources

Publications for Barrett Esophagus

About this section

Articles related to Barrett Esophagus:

(show top 50) (show all 6831)
# Title Authors PMID Year
1
Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. 61 56 6
21791690 2011
2
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. 61 56
22961001 2012
3
Familial Barrett's esophagus associated with adenocarcinoma. 61 56
1551547 1992
4
Barrett's esophagus and adenocarcinoma: from the family to the gene. 61 56
1551552 1992
5
Familial gastroesophageal reflux and development of Barrett's esophagus. 61 56
4003988 1985
6
Barrett's esophagus: inherited epithelium or inherited reflux? 61 56
6886360 1983
7
Barrett esophagus in sexagenarian identical twins. 61 56
6683290 1983
8
Barrett's esophagus: a review. 61 56
6337489 1983
9
CDX1 is an important molecular mediator of Barrett's metaplasia. 56
15894614 2005
10
Demographic and phenotypic features of 70 families segregating Barrett's oesophagus and oesophageal adenocarcinoma. 56
12960209 2003
11
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. 56
10080844 1999
12
Familial Barrett's oesophagus? 56
3721391 1986
13
Columnar cell-lined esophagus: assessment of etiology and treatment. A 22 year experience. 56
1271833 1976
14
The columnar-lined esophagus (Barrett syndrome)--an acquired condition? 56
5935228 1966
15
The oesophagus lined with gastric mucous membrane. 56
13077502 1953
16
Chronic peptic ulcer of the oesophagus and 'oesophagitis'. 56
14791960 1950
17
Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. 54 61
20138038 2010
18
The role of oxidative DNA damage, DNA repair, GSTM1, SOD2 and OGG1 polymorphisms in individual susceptibility to Barrett's esophagus. 54 61
20056743 2010
19
Colocalization of MnSOD expression in response to oxidative stress. 54 61
19623544 2010
20
Expression of resistin-like molecule beta in gastric cancer: its relationship with clinicopathological parameters and prognosis. 54 61
19967544 2010
21
Preoperative gastric acid secretion and the risk to develop Barrett's esophagus after esophagectomy for chagasic achalasia. 54 61
19756883 2009
22
Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. 54 61
19638963 2009
23
Adenocarcinoma of the esophagogastric junction: relationship between clinicopathological data and p53, cyclin D1 and Bcl-2 immunoexpressions. 54 61
20232013 2009
24
Regulation of CDX2 expression in esophageal adenocarcinoma. 54 61
19415720 2009
25
Pathogenesis of Barrett's esophagus: bile acids inhibit the Notch signaling pathway with induction of CDX2 gene expression in human esophageal cells. 54 61
19789031 2009
26
Inhibition of nucleostemin upregulates CDX2 expression in HT29 cells in response to bile acid exposure: implications in the pathogenesis of Barrett's esophagus. 54 61
19449081 2009
27
Increased p53 expression in the malignant transformation of Barrett's esophagus is accompanied by an upward shift of the proliferative compartment. 54 61
18752044 2009
28
Keratin 7 expression as an early marker of reflux-related columnar mucosa without intestinal metaplasia in the esophagus. 54 61
19396034 2009
29
Immunoreactivity of cytokeratins 7 and 20 in goblet cells and columnar blue cells in patients with endoscopic evidence of Barrett's esophagus. 54 61
19578614 2009
30
Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus. 54 61
19027227 2009
31
Bile acid alone, or in combination with acid, induces CDX2 expression through activation of the epidermal growth factor receptor (EGFR). 54 61
18854960 2009
32
P53 and Ki-67 overexpression in gastroesophageal reflux disease--Barrett's esophagus and adenocarcinoma sequence. 54 61
19302208 2009
33
What is the clinical significance of stromal angiogenesis in Barrett's esophagus? 54 61
19120900 2008
34
The effect of retinoic acid and deoxycholic acid on the differentiation of primary human esophageal keratinocytes. 54 61
18368492 2008
35
Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study. 54 61
18980994 2008
36
Helicobacter pylori and non-malignant diseases. 54 61
18783518 2008
37
p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus. 54 61
18665038 2008
38
Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. 54 61
17849424 2008
39
CDX2 and villin are useful markers of intestinal metaplasia in the diagnosis of Barrett esophagus. 54 61
18343784 2008
40
Barrett's esophagus and cardiac intestinal metaplasia: two conditions within the same spectrum. 54 61
18414711 2008
41
Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. 54 61
18349295 2008
42
REG Ialpha protein expression in Barrett's esophagus. 54 61
18289358 2008
43
Aneuploidy and high expression of p53 and Ki67 is associated with neoplastic progression in Barrett esophagus. 54 61
18334729 2008
44
p16 mutation spectrum in the premalignant condition Barrett's esophagus. 54 61
19043591 2008
45
Cytokeratin and CDX-2 expression in Barrett's esophagus. 54 61
18224560 2008
46
Photodynamic therapy of Barrett's esophagus: ablation of Barrett's mucosa and reduction in p53 protein expression after treatment. 54 61
18383889 2008
47
p53 in esophageal adenocarcinoma: a critical reassessment of mutation frequency and identification of 72Arg as the dominant allele. 54 61
17982662 2007
48
Over-expression of cyclooxygenase-2 in endoscopic biopsies of ectopic gastric mucosa. 54 61
17934641 2007
49
COX-2 mRNA expression is significantly increased in acid-exposed compared to nonexposed squamous epithelium in gastroesophageal reflux disease. 54 61
17619937 2007
50
Molecular analysis of the p53 gene in patients with intestinal metaplasia of the cardia and Barrett's esophagus: characterization by sequencing. 54 61
17404881 2007
Sources

Variations for Barrett Esophagus

About this section

ClinVar genetic disease variations for Barrett Esophagus:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MSR1 NM_138715.3(MSR1):c.760C>G (p.Leu254Val)SNV Pathogenic 29779 rs387906645 8:16021631-16021631 8:16164122-16164122
2 CTHRC1 NM_138455.4(CTHRC1):c.131A>C (p.Gln44Pro)SNV Pathogenic 30848 rs387907029 8:104384015-104384015 8:103371787-103371787
3 ASCC1 NM_001198800.3(ASCC1):c.869A>G (p.Asn290Ser)SNV Benign/Likely benign 31129 rs146370051 10:73892817-73892817 10:72133059-72133059

Copy number variations for Barrett Esophagus from CNVD:

7 (show top 50) (show all 157)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 18052 1 143700001 144900000 Amplification BCL9 Esophageal adenocarcinoma
2 19685 1 151000001 155000000 Amplification SKI Esophageal adenocarcinoma
3 21958 1 163432534 163614111 Gain and loss LMX1A Barrett''s syndrome
4 25140 1 184717073 186846060 Gain and loss PLA2G4A Barrett''s syndrome
5 25141 1 184717073 186846060 Gain and loss PTGS2 Barrett''s syndrome
6 29301 1 2300000 5400000 Copy number Esophageal adenocarcinoma
7 33578 1 46425202 46624292 Loss RAD54L Barrett''s syndrome
8 37058 1 84900000 107200000 Loss F3 Esophageal adenocarcinoma
9 39044 10 108165938 109275992 Loss SORCS1 Barrett''s syndrome
10 39081 10 109092539 133471230 Loss BUB3 Barrett''s syndrome
11 39082 10 109092539 133471230 Loss C10orf119 Barrett''s syndrome
12 39083 10 109092539 133471230 Loss NANOS1 Barrett''s syndrome
13 39407 10 114856262 115024106 Loss TCF7L2 Barrett''s syndrome
14 47055 10 89500000 92900000 Copy number Esophageal adenocarcinoma
15 49101 11 102900000 110400000 Copy number Esophageal adenocarcinoma
16 50933 11 120168346 133686875 Loss CHEK1 Barrett''s syndrome
17 50934 11 120168346 133686875 Loss ETS1 Barrett''s syndrome
18 50935 11 120168346 133686875 Loss TIRAP Barrett''s syndrome
19 52231 11 149520 6642613 Loss MUC6 Barrett''s syndrome
20 52232 11 149520 6642613 Loss RHOG Barrett''s syndrome
21 53078 11 2400000 5900000 Copy number CDKN1C Esophageal adenocarcinoma
22 54793 11 474042 626401 Loss HRAS Barrett''s syndrome
23 54794 11 474042 626401 Loss MUPCDH Barrett''s syndrome
24 54795 11 474042 626401 Loss RASSF7 Barrett''s syndrome
25 54796 11 474042 626401 Loss RNH1 Barrett''s syndrome
26 54797 11 474042 626401 Loss SCT Barrett''s syndrome
27 57455 11 63400000 77100000 Gain CCND1 Esophageal adenocarcinoma
28 57457 11 63400000 77100000 Gain EMS1 Esophageal adenocarcinoma
29 57458 11 63400000 77100000 Gain FGF3 Esophageal adenocarcinoma
30 60370 11 8555485 8795697 Loss ST5 Barrett''s syndrome
31 60371 11 8555485 8795697 Loss STK33 Barrett''s syndrome
32 64928 12 133416937 133464204 Copy number CHFR Esophageal adenocarcinoma
33 76216 13 28900000 32200000 Gain BRCA2 Esophageal adenocarcinoma
34 80630 13 95000000 115169878 Gain ABCC4 Esophageal adenocarcinoma
35 80631 13 95000000 115169878 Gain ING1 Esophageal adenocarcinoma
36 83864 14 22278370 23705612 Gain and loss MMP14 Barrett''s syndrome
37 83865 14 22278370 23705612 Gain and loss PCK2 Barrett''s syndrome
38 86372 14 58681498 106175506 Gain and loss FOXN3 Barrett''s syndrome
39 86373 14 58681498 106175506 Gain and loss MAX Barrett''s syndrome
40 86374 14 58681498 106175506 Gain and loss MLH3 Barrett''s syndrome
41 92864 15 44800000 63700000 Loss B2M Esophageal adenocarcinoma
42 95624 15 78300000 102531392 Loss IGF1R Esophageal adenocarcinoma
43 105274 16 77215302 77345302 Loss WWOX Barrett''s syndrome
44 105374 16 7900000 10500000 Copy number Esophageal adenocarcinoma
45 106764 17 1 20774742 Copy number MYBBP1A Esophageal adenocarcinoma
46 106765 17 1 20774742 Copy number TP53 Esophageal adenocarcinoma
47 108120 17 18863807 19044654 Loss GRAP Barrett''s syndrome
48 109777 17 2912016 3092354 Gain and loss Barrett''s syndrome
49 109778 17 2912016 3092354 Gain and loss Esophageal adenocarcinoma
50 110805 17 34303536 34308523 Gain SCYA3 Esophageal adenocarcinoma
Sources

Expression for Barrett Esophagus

About this section
Search GEO for disease gene expression data for Barrett Esophagus.
Sources

Pathways for Barrett Esophagus

About this section

Pathways related to Barrett Esophagus according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Pathways in cancer 36
12.53 TP53 PTGS2 GSTP1 CDKN2A CCND1
2
Gastric cancer 36
Show member pathways
 12.32 TP53 GSTP1 CDX2 CDKN2A CCND1
3
WNT Signaling 63
12.16 TP53 PTGS2 GAST CCND1
4
Small cell lung cancer 36
11.57 TP53 PTGS2 CCND1
5
Platinum drug resistance 36
11.41 TP53 GSTP1 CDKN2A
6
Bladder cancer 36 1
11.36 TP53 CDKN2A CCND1
7
Photodynamic therapy-induced AP-1 survival signaling. 1
10.84 TP53 CDKN2A CCND1
8
Hepatitis C and Hepatocellular Carcinoma 1
10.51 TP53 PTGS2 CCND1
9
Gastric acid production 1
10 MUC6 GAST
Sources

GO Terms for Barrett Esophagus

About this section

Cellular components related to Barrett Esophagus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 TFF3 TFF2 TFF1 MUC5AC GSTP1 GDF7
2 extracellular region GO:0005576 9.28 TFF3 TFF2 TFF1 MUC6 MUC5AC GSTP1

Biological processes related to Barrett Esophagus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular oxidant detoxification GO:0098869 9.33 PTGS2 GSTP1 GPX2
2 replicative senescence GO:0090399 9.26 TP53 CDKN2A
3 mitotic G1 DNA damage checkpoint GO:0031571 8.96 TP53 CCND1
4 maintenance of gastrointestinal epithelium GO:0030277 8.92 TFF3 TFF2 TFF1 MUC6
Sources

Sources for Barrett Esophagus

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....